{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055585","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.847104+00:00","generated_at":"2026-06-02T09:50:08.090308+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Personalis Q1 revenue $19.5M beats guidance; raises FY24 revenue outlook to $76-78M","bullets":["Q1 2024 revenue $19.5M (up 3% YoY), exceeding upper-end of guidance; pharma testing revenue grew 55% to $9.8M.","Net loss narrowed to $13.0M from $28.7M in Q1 2023, aided by $4.8M non-cash gain on Tempus warrants.","Raised FY2024 total revenue guidance to $76-78M from $73-75M; non-GAAP net loss improved to ~$77M from prior ~$80M.","Cash and short-term investments $95.4M; Q2 2024 revenue expected $19.5-20.5M.","NeXT Personal MRD test published in Oncotarget; 338 molecular tests delivered; five ASCO abstracts accepted."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055585","json":"https://secwatch.observer/filing/0000950170-24-055585.json","markdown":"https://secwatch.observer/filing/0000950170-24-055585.md","text":"https://secwatch.observer/filing/0000950170-24-055585.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000095017024055585/0000950170-24-055585-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000095017024055585/psnl-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:50:08.090308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"049df2d9e665b98b1fe21c20f7df3eb46d4c146b","claim":"Personalis, Inc. reported first quarter of 2024 ended March 31, 2024 results: revenue total company revenue of $19.5 million, net income Net loss of $13.0 million. Guidance raised.","evidence_excerpt":"delivered in Q1, reflecting 100% engagement of NeXT Personal Dx early access clients and strong NeXT Dx growth. “We began 2024 with strong execution as we delivered revenue of $19.5 million in the first quarter, exceeding the upper-end of our guidance range, and we continue to develop compelling NeXT Personal clinical evidence as we work towards obtaining Medicare","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527753/000095017024055585/0000950170-24-055585-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024 ended March 31, 2024"},{"label":"Revenue","value":"total company revenue of $19.5 million"},{"label":"Net income","value":"Net loss of $13.0 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}